All In MedTech

Device Trial Radar · NCT02774434

Efficacy Study of the Draeger Jaundice Meter (JM-105) in Neonates of ≥ 24 Weeks of Gestational Age

Efficacy Study of the Draeger Jaundice Meter (JM-105) in Providing TcB Measurements to Estimate TSB in Neonates of ≥ 24 Weeks of Gestational Age Who Have and Have Not Undergone Phototherapy

Last checked: Nov 20, 2026Latest source record: Feb 7, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

464

Actual

Start

Nov 2016

Primary completion

Jun 2018

Study completion Jun 2018

Sponsor

Lead sponsor
Draeger Medical Systems, Inc.Not on our public-company list
Sponsor type
Industry
First posted
May 17, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Screening
Who can join
All sexes, from 24 weeks, up to 40 weeks
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Canadian Pediatric Society recently published guidelines to monitor bilirubin levels and as part of standard of care all hospitalized newborns are routinely monitored for the development of high bilirubin or jaundice every 8-12 hours. One device approved and used in both Canada and the United States is the Draeger Jaundice Meter JM-103, a non-invasive medical device. It has been proven to be effective in patients \>35 weeks gestational age. Recently the JM-103 has been upgraded to include a bigger touch screen, greater storage and functionality. The rest of the features of the JM-103 and JM-105 are identical. In order to test the accuracy of the JM-105 neonates from ≥ 24 weeks gestational age who have or have not undergone phototherapy will be prospectively monitored for transcutaneous bilirubin (TcB) using the JM-105. The measurements will be compared to a physician-ordered total serum bilirubin (TSB).

Conditions

  • Hyperbilirubinemia
  • Neonatal Jaundice

Interventions

  • JM-105Device

    Measurement of TcB via the JM-105 device

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Accuracy of TcB measured with the JM-105 device in predicting the Serum Bilirubin measurements performed on blood samplesTime frame: Within 15 minutes of blood sample taking

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Saint Michael's Hospital

    Toronto, Ontario, Canada

  • Mount Sinai Hospital

    Toronto, Ontario, Canada

  • Hamilton Health Science Centre

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.